An update on pilus-based vaccine development to prevent Group A Streptococcal infections (#181)

5:30 PM

Jacelyn MS Loh

Poster Session 1

Immune Responses In Siblings With Acute Rheumatic Fever – A Case Study (#219)

5:30 PM

Natalie Lorenz

Poster Session 2

Where did all the antibodies go? Exploring Immunity Gaps to Group A Streptococcus and other endemic respiratory pathogens following pandemic Restrictions in Aotearoa New Zealand (#182)

5:30 PM

Natalie Lorenz

Poster Session 1

A novel approach to assess antigen specific Fc-mediated antibody functions induced by Streptococcus pyogenes pharyngitis (118113)

4:25 PM

Kaneka Chheng

Plenary 4 - Rapid Fire Session

The Emergence and Impact of M1_UK on Invasive Group A Streptococcus Disease in Aotearoa New Zealand (#154)

5:30 PM

Anna Vesty

Poster Session 1

Rapua te mea nagro ka tau- a qualitative, Indigenous-informed approach to vaccine development. (118028)

2:42 PM

Anneka Anderson

Plenary 3 - Big Picture Vaccine Development

Addressing Evidence Gaps in ARF Treatment - from the Aotearoa hydroxychloroquine pilot to an international adaptive platform trial  (118488)

11:51 AM

Rachel Webb

Plenary 11 - Lancefield Time Machine - The Shape of Things to Come

Rapua te mea ngaro ka tau: culturally responsive governance applied to vaccine development (#277)

5:30 PM

Shannon Leilua

Poster Session 2

A peptide epitope biomarker signature that differentiates acute rheumatic fever from related clinical presentations (118534)

12:03 PM

Tim Barnett

Plenary 11 - Lancefield Time Machine - The Shape of Things to Come

Antibody responses to conserved peptide sequences from the M-protein of group A streptococcus (#256)

5:30 PM

David J McMillan

Poster Session 2

How much is too much? Deciphering exaggerated immune responses in acute rheumatic fever (122376)

9:00 AM

Nikki Moreland

Plenary 7 - Autoimmunity and Its Long Tail